Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06408181
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-05-01
Brief Title:
APPLE Aspirin to Prevent Pregnancy Loss and Preeclampsia
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
APPLE Aspirin to Prevent Pregnancy Loss and Preeclampsia
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APPLE
Brief Summary:
The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women The main questions it aims to answer are
Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations Participants will begin taking at no later than 6 weeks 6 days gestational age either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery
Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations Participants will begin taking at no later than 6 weeks 6 days gestational age either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01HD112308-01 | NIH | None | httpsreporternihgovquickSearch1R01HD112308-01 |